Abionyx Pharma SA
PAR:ABNX

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
PAR:ABNX
Watchlist
Price: 3.89 EUR Market Closed
Market Cap: 135.9m EUR

Abionyx Pharma SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abionyx Pharma SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Abionyx Pharma SA
PAR:ABNX
Revenue
€4.3m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Revenue
€291.4m
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
17%
Nanobiotix SA
PAR:NANO
Revenue
-€14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Revenue
€13.6m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Revenue
$112.6m
CAGR 3-Years
45%
CAGR 5-Years
-3%
CAGR 10-Years
10%
DBV Technologies SA
PAR:DBV
Revenue
$3.8m
CAGR 3-Years
-27%
CAGR 5-Years
-30%
CAGR 10-Years
-3%
No Stocks Found

Abionyx Pharma SA
Glance View

Market Cap
135.3m EUR
Industry
Biotechnology

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

ABNX Intrinsic Value
3.41 EUR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Abionyx Pharma SA's Revenue?
Revenue
4.3m EUR

Based on the financial report for Jun 30, 2025, Abionyx Pharma SA's Revenue amounts to 4.3m EUR.

What is Abionyx Pharma SA's Revenue growth rate?
Revenue CAGR 3Y
10%

Over the last year, the Revenue growth was -11%. The average annual Revenue growth rates for Abionyx Pharma SA have been 10% over the past three years .

Back to Top